RxDoctor Payments Data

Sohail Shariff, MD

Family Medicine · Coalport, PANPI 1194730929

Payments from drug & device makers

$1,466in general payments, 2019–2025

Across 83 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$241
  • AbbVie$210
  • Pfizer$162
  • Lilly USA, LLC$123
  • Astellas Pharma US Inc$114
  • Amarin Pharma, Inc.$70
  • plus $546 from 16 others

What the payments were for

  • Food & beverage$1,36693%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,466 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$207,918
Medicare patients
742
Services billed
2,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$57,590
OzempicSemaglutide40$48,095
JanuviaSitagliptin Phosphate21$32,931
JardianceEmpagliflozin26$23,486
XareltoRivaroxaban16$17,592
ShingrixVaricella-Zoster Ge/As01b/Pf77$16,195
Breo ElliptaFluticasone/Vilanterol27$13,584
MyrbetriqMirabegron15$11,319
AbrysvoRsv Vacc, Pref A And Pref B/Pf33$10,053
TradjentaLinagliptin12$6,695
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,454
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,046
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,307
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$2,909
Albuterol Sulfate HfaAlbuterol Sulfate67$2,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$162$67,64388 claims
Novo NordiskOzempic$241$48,09540 claims
MerckJanuvia$36$32,93121 claims
GSKShingrix, Breo Ellipta$35$29,779104 claims
Johnson & JohnsonXarelto$70$17,59216 claims
Astellas Pharma US IncMyrbetriq$114$11,31915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Coalport

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →